- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CHINA YONGXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 64,90 | +0,68 % | Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook | ||
| CSPC PHARMA | 0,872 | +1,85 % | CSPC PHARMA (01093): UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025 | ||
| SELLAS LIFE SCIENCES | 1,618 | +2,02 % | SELLAS Life Sciences raises $31 million through warrant exercise | ||
| ACADIA PHARMACEUTICALS | 19,650 | -0,30 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
UBS Global Healthcare Conference
Fireside Chat: Monday, November 10... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 18,395 | +0,03 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 366,80 | +0,94 % | Madrigal Pharmaceuticals: +40% seit Kauftipp im August - und jetzt? | Nach einem rasanten Kursanstieg und einer beispiellosen Marktdynamik rund um das Lebermedikament Rezdiffra richtet sich der Blick der Anleger von Madrigal Pharmaceuticals auf die bevorstehenden Quartalsergebnisse.... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,042 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Announce Amendment to Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,976 | -0,30 % | Opus Genetics, Inc.: Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) | Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 3,720 | +5,08 % | Savara schließt Kapitalerhöhung über 149,5 Millionen US-Dollar ab | ||
| VIRACTA THERAPEUTICS | 0,090 | 0,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| GALECTIN THERAPEUTICS | 4,980 | +1,22 % | GALECTIN THERAPEUTICS INC - 8-K, Current Report | ||
| BIODEXA PHARMACEUTICALS | 6,290 | +0,16 % | Biodexa Pharmaceuticals PLC: Interim results for the six months ended June 30, 2025 | September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 1,155 | -2,12 % | NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards | EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,061 | -18,67 % | NEURIZON THERAPEUTICS LIMITED: Section 708A Cleansing Statement |
Das Unternehmen CHINA YONGXIN PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHINA YONGXIN PHARMACEUTICALS INC finden Sie auf Wallstreet Online.